YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Alzheimer's Disease International ("ADI") observes Sept. 21 as World Alzheimer's Day, while September is marked as World Alzheimer's Month to raise awareness about Alzheimer's disease (AD) and other forms of dementia. The 2026 campaign — T…
By Mike Sheikh Parkinson's Disease has challenged drug developers for generations, but Jupiter Neurosciences (NASDAQ: JUNS) is betting that a streamlined clinical plan can break the stalemate. The market isn't recognizing the story yet wit…
Prothena Corporation PRTA reported second-quarter 2026 adjusted loss per share (excluding restructuring costs) of 32 cents, narrower than the Zacks Consensus Estimate of a loss of 39 cents per share. In the year-ago quarter, the company ha…
Net cash used in operating and investing activities was $25.7 million in the second quarter and net cash provided by operating and investing activities was $3.2 million for the first six months of 2026; quarter-end cash and restricted cash…
Shares of Prothena Corporation PRTA have gained around 11% over the past six months compared with the industry's 5.1% growth. The rally has been driven by growing investor confidence in the continued advancement across Prothena's late-stag…
Adaptive Biotechnologies (ADPT) shares rallied 9.7% in the last trading session to close at $18.73. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the…
Over the last 7 days, the United States market has risen by 1.3%, contributing to a robust 28% increase over the past year, with earnings expected to grow by 17% annually. In this thriving environment, growth companies with high insider ow…
Prothena Corporation PRTA reported first-quarter 2026 adjusted earnings per share (excluding restructuring costs) of 52 cents. The Zacks Consensus Estimate was a loss of 31 cents per share. In the year-ago quarter, the company had incurred…
Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million Prothena updates projected full year 2026 net cash used in operating…
KalVista Pharmaceuticals(NASDAQ:KALV), a developer of oral therapies for rare diseases, closed Wednesday at $26.67, up 38.62%. The stock moved higher after news that Italy’s Chiesi Group will acquire KalVista for $27 per share in cash. Inv…
In the last week, the United States market has stayed flat, but over the past 12 months, it has risen by an impressive 29%, with earnings forecasted to grow by 16% annually. In this environment of growth and stability, companies with high…
Coramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Coramitug is being evaluated by Novo Nordisk in the ongoing Phase 3 CLEOPATTRA clinical trial in ~1280 participan…
AstraZeneca AZN announced positive data from a late-stage clinical program that consisted of three phase III studies evaluating its pipeline candidate, efzimfotase alfa (ALXN1850), for treating certain patients with hypophosphatasia (HPP),…
Over the last 7 days, the United States market has experienced a 3.5% decline, yet it remains up by 14% over the past year with earnings forecasted to grow by 15% annually. In this environment, growth companies with high insider ownership…
Sanofi SNY announced that the European Commission has granted a conditional marketing authorization to Rezurock (belumosudil) for treating chronic graft-versus-host disease (GVHD) in adults and in children aged 12 years and above weighing…
Rocket Pharmaceuticals RCKT announced that the FDA has granted accelerated approval to its gene therapy Kresladi (marnetegragene autotemcel) to treat patients with severe leukocyte adhesion deficiency-I (LAD-I), an ultra-rare genetic disor…
It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have added about 24.2% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings…
It has been about a month since the last earnings report for Jazz Pharmaceuticals (JAZZ). Shares have lost about 3.9% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent negative trend continu…
DUBLIN, March 21, 2026--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced p…
Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Prothena has now earned $150 million to date of the $1.2 billion total eligible milestone payments from Novo Nor…
(RTTNews) - Prothena Corporation plc (PRTA) announced that its board has authorized a share repurchase plan allowing the company to buy back up to $100 million of its outstanding ordinary shares. As of December 31, 2025, Prothena reported…
* Prothena Corporation (PRTA [https://seekingalpha.com/symbol/PRTA]) on Friday said that its board had authorized a share repurchase plan of up to $100 million of the company’s outstanding ordinary shares. * The biotechnology company said…
DUBLIN, February 27, 2026--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announce…
Prothena Corporation PRTA reported fourth-quarter 2025 adjusted loss per share (excluding restructuring costs) of 45 cents, in line with the Zacks Consensus Estimate. In the year-ago quarter, the company had incurred a loss of $1.08 per sh…
Prothena logo Key Points Partner programs advanced to late-stage trials: Roche’s prasinezumab (PARAISO) and Novo Nordisk’s coramitug (CLEOPATTRA) moved into Phase 3 (≈900 and ≈1,280 patients respectively, primary completions ~2029) after s…
Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was $308.4 million Prothena expects the full…
Shares of Prothena Corporation PRTA have plunged 36.8% over the past year against the industry’s 19.6% rise. The decline can be attributed to pipeline setbacks, most notably the failure and subsequent termination of its wholly owned candid…
What Changed in the Price Target Narrative Analysts lifting their Prothena price target to US$36, from US$15, are tying that view to how they see the partnered pipeline converting into future royalty and milestone cash flows rather than to…
Prothena’s fair value estimate has been nudged higher from $18.33 to $20.33 per share as analysts grow more confident in the company’s partnered pipeline and its potential to drive stronger long term revenue. The model now assumes faster t…
Novo Nordisk’s Phase 2 data for coramitug supports ongoing Phase 3 CLEOPATTRA clinical trial in patients with ATTR amyloidosis with cardiomyopathy Coramitug is being developed by Novo Nordisk as part of their up to $1.2 billion acquisition…
Prothena Corporation PRTA reported third-quarter 2025 adjusted loss per share (excluding restructuring costs) of 67 cents, much wider than the Zacks Consensus Estimate of a loss of 60 cents. In the year-ago quarter, the company reported a…
Prothena (PRTA) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $1.1 per share a year ago. These figures are adjusted for non-recurring items. This quarter…
Net cash used in operating and investing activities was $40.6 million and $140.4 million for the third quarter and first nine months of 2025, respectively; quarter-end cash and restricted cash position was $331.7 million Roche to initiate…
This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return potential, read our free article: 10 High-Potential Small-Caps With Market Cap Under $1B. We came across a bullish thesis…
This article first appeared on GuruFocus. Bristol Myers Squibb (NYSE:BMY) just got a boost in its Alzheimer's program after the FDA granted Fast Track designation to its experimental drug BMS-986446, now in phase 2 testing for patients in…
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease Fast Track Designation recognizes the potential of anti-MTBR tau to be an important treatment…